Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 4/2005

Ausgabe 4/2005

Inhaltsverzeichnis ( 13 Artikel )

01.08.2005 | Ausgabe 4/2005

Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid

Stefan R. Vink, Jan H. M. Schellens, Wim J. van Blitterswijk, Marcel Verheij

01.08.2005 | Ausgabe 4/2005

Enhanced P53 and BAX gene expression and apoptosis in A549 cells by cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP

Beata Kosmider, Izabela Wojcik, Regina Osiecka, Jacek Bartkowiak, Elzbieta Zyner, Justyn Ochocki, Pawel Liberski

01.08.2005 | Ausgabe 4/2005

A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines

Kongming Wu, Mark D’Amico, Chenguang Wang, Chris Albanese, Richard G. Pestell, Sridhar Mani

01.08.2005 | Ausgabe 4/2005

A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer

Kim N. Chi, Stephen K. Chia, Ross Dixon, Michael J. Newman, Vince J. Wacher, Branimir Sikic, Karen A. Gelmon

01.08.2005 | Ausgabe 4/2005

Human metabolism of [14C]indisulam following i.v. infusion in cancer patients

Jan-Hendrik Beumer, Michel J. X. Hillebrand, Dick Pluim, Hilde Rosing, Karen Foley, S. Murray Yule, Jan H. M. Schellens, Jos H. Beijnen

01.08.2005 | Ausgabe 4/2005

Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer

Takahiko Sugiura, Yutaka Ariyoshi, Shunichi Negoro, Shinichiro Nakamura, Harumichi Ikegami, Minoru Takada, Takashi Yana, Masahiro Fukuoka

01.08.2005 | Ausgabe 4/2005

DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors

Moritz N. Wente, Jörg Kleeff, Markus W. Büchler, Jantien Wanders, Peter Cheverton, Stephen Langman, Helmut Friess

01.08.2005 | Ausgabe 4/2005

Gemcitabine and mitoxantrone in metastatic breast cancer: A phase-I-study

Peter Schmid, Bernd Flath, Konstantin Akrivakis, Volker Heilmann, Hans-Günther Mergenthaler, Orhan Sezer, Rolf Kreienberg, Kurt Possinger

01.08.2005 | Ausgabe 4/2005

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

Susan M. Chang, Patrick Wen, Timothy Cloughesy, Harry Greenberg, David Schiff, Charles Conrad, Karen Fink, H. Ian Robins, Lisa De Angelis, Jeffrey Raizer, Kenneth Hess, Ken Aldape, Kathleen R. Lamborn, John Kuhn, Janet Dancey, Michael D. Prados, North American Brain Tumor Consortium and the National Cancer Institute

01.08.2005 | Ausgabe 4/2005

BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR)

R.-D. Hofheinz, C. Porta, G. Hartung, A. Santoro, A.-R. Hanauske, K. Kutz, A. Stern, P. Barbieri, E. Verdi, R. Hehlmann, A. Hochhaus

01.08.2005 | Ausgabe 4/2005

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

Nicolas Tsavaris, Christos Kosmas, Helias Skopelitis, Panagiotis Gouveris, Petros Kopteridis, Dioynissis Loukeris, Frantzeska Sigala, Alexandra Zorbala-Sypsa, Evangelos Felekouras, Efstathios Papalambros

01.08.2005 | Erratum | Ausgabe 4/2005

Phase I Study of Tomudex and Doxorubicin in Patients with Locally Advanced, Inoperable or Metastatic Cancer (IND.98)

Editorial Board

01.08.2005 | Erratum | Ausgabe 4/2005

Pomegranate (Punica granatum) Pure Chemicals Show Possible Synergistic Inhibition of Human PC-3 Prostate Cancer Cell Invasion Across Matrigeltm

Editorial Board

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise